AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Nucor, you generally need to believe in its ability to earn solid returns through the steel cycle while managing big capital projects and trade exposure. The new shelf registration and Indiana expansion do not materially change the near term picture, where execution on large projects and uncertainty around steel tariffs remain the key catalyst and primary risk.
The new omnibus shelf registration is the most relevant recent move, because it gives Nucor flexibility to raise capital across debt, common and preferred stock classes. For investors focused on upcoming catalysts such as the West Virginia sheet mill and ongoing buybacks, this additional financing option could influence how Nucor balances growth spending with returning cash to shareholders if funding needs change.
Yet alongside these positives, investors should be aware of how future shifts in trade policy could...
Read the full narrative on Nucor (it's free!)
Nucor's narrative projects $40.5 billion revenue and $4.5 billion earnings by 2029. This requires 3.9% yearly revenue growth and a $1.6 billion earnings increase from $2.9 billion today.
Uncover how Nucor's forecasts yield a $283.56 fair value, a 16% upside to its current price.
More optimistic analysts were already modeling revenue of about US$40.6 billion and earnings near US$4.0 billion by 2029, which assumes robust returns on heavy capex even as large projects like the West Virginia sheet mill carry meaningful risk if demand or utilization fall short.
Explore 3 other fair value estimates on Nucor - why the stock might be worth as much as 72% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com